Volatile biotech Dendreon (DNDN)
has been a painful lesson for some investors that there's a big
difference between good technology and a good stock. The company
deserves, and gets, plenty of credit for developing the first-ever
cancer vaccine, but serious questions about efficacy, cost-benefit,
competition and intrinsic profitability have lingered from the moment of
approval Now that repeated sales disappoints have knocked the stock
down significantly over the past year, the stock may at last be priced
with more rational expectations in mind.
Please continue here:
For Dendreon There's A Little Light, But A Lot Of Tunnel
No comments:
Post a Comment